Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
Current and Future State of US Biosimilars
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
The Threat to Preferred Pharmacy Networks
Provider networks are a well-known tool health insurance companies use to keep down the cost of care.
1 big thing: Congress takes on PBMs
“Alex Brill, CEO of the economic consulting firm Matrix Global Advisors and a senior fellow at AEI, said it is “unnecessary” to require PBMs to pass the rebates along to plans.”
Humira Competitors Don’t Guarantee Lower Patient Drug Costs
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
- A Tip Exemption Is Not Sound Tax Policy
- Implications of Cannabis Legalization for the US Federal Budget
- Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
- A Balanced Plan for Fiscal Stability and Economic Growth
- Despite Headwinds, Biosimilars Market Is Growing in 2024
- IRS says it will deny most claims of pandemic tax credit for employers
- Trump Talks Taxes and Tariffs
- Beware the Baseline Manipulator
- Patent Thicket Déjà Vu
- Will Congress Finally Act on Patent Thickets?
